LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
63 hedge funds and large institutions have $69.8M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 19 closing their positions.
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
3% more funds holding
Funds holding: 61 → 63 (+2)
29% less call options, than puts
Call options by funds: $5K | Put options by funds: $7K
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
46% less capital invested
Capital invested by funds: $128M → $69.8M (-$58.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$929K |
| 2 |
Renaissance Technologies
New York
|
+$491K |
| 3 |
Millennium Management
New York
|
+$480K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$389K |
| 5 |
E
Ergoteles
New York
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.01M |
| 2 |
BlackRock
New York
|
-$3.88M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.06M |
| 4 |
JP Morgan Chase
New York
|
-$939K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$807K |
LOGC Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2021, worth a combined $69.8M — down 46% from $128M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LOGC positions and 19 closed out — a net gain of 2 holders — while 11 added to existing stakes and 16 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $929K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.01M sold.
- 63 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2021, up from 61 in Q1 2021.
- Funds reported $69.8M of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2021, down 46% quarter-over-quarter.
- 21 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of +2 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2021 was Sio Capital Management, an estimated $929K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2021 was EcoR1 Capital, an estimated $5.01M sold.
Based on aggregated 13F filings for Q2 2021.